Clinical Trial

Anti-CEACAM5 ADC Precemtabart Tocentecan (M9140) in Chinese Participants With Solid Tumors

Active, Not Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
The purpose of this study is to evaluate the safety and early clinical activity of M9140 in Chinese participants with locally advanced or metastatic colorectal cancer (CRC).
Protocol Amendment History 2 changes
notable Primary completion pushed: 2026-05-07 -> 2026-09-30 2026-04-24
minor Completion pushed: 2026-05-07 -> 2026-09-30 2026-04-24
Trial Details
NCT Number NCT06806046
Lead Sponsor Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
Collaborators: Merck KGaA, Darmstadt, Germany
Conditions Solid Tumors, Colorectal Cancer
Enrollment 12 participants
Start Date 2024-12-20
Primary Completion 2026-09-30 (estimated)
Study Completion 2026-09-30 (estimated)
Updated on ClinicalTrials.gov 2026-08-11